Skip to main content
SpringerLink
Log in

Typ-2-Diabetes

Kardiovaskuläre Sicherheit oraler Antidiabetika

Cardiovascular safety concerns of glucose-lowering drugs

  • FORTBILDUNG . SEMINAR
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Da das Schicksal von Typ-2-Diabetikern vor allem von den kardiovaskulären Komorbiditäten abhängt, dürfen Antidiabetika weder Herz noch Gefäße schädigen. Für manche Antidiabetika ist dies nachgewiesen. Andere schützen sogar vor Herz-Kreislauf-Komplikationen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Saydah SH, Eberhardt MS, Loria CM et al. Age and the burden of death attributable to diabetes in the United states. Am J Epidemiol. 2002;156:714–19

    Article  PubMed  Google Scholar 

  2. Franco OH, Steyerberg EW, Hu FB et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167:1145–51

    Article  PubMed  Google Scholar 

  3. Almdal T, Scharling H, Jensen JS et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422–42.

    Article  PubMed  Google Scholar 

  4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53

  5. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89

    Article  CAS  PubMed  Google Scholar 

  6. Gæde P, Oellgaard J, Carstensen B et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016:59:2298. doi:10.1007/s00125-016-4065-6

    Article  PubMed  Google Scholar 

  7. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59

    Article  CAS  PubMed  Google Scholar 

  8. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72

    Article  CAS  PubMed  Google Scholar 

  9. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39

    Article  CAS  PubMed  Google Scholar 

  10. European Medicines Agencies (EMA). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed May 27, 2016.

  11. Eurich DT, Weir DL, Majumdar SR et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395–402

    Article  CAS  PubMed  Google Scholar 

  12. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42

    Article  CAS  PubMed  Google Scholar 

  13. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.

    Article  CAS  PubMed  Google Scholar 

  14. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35

    Article  CAS  PubMed  Google Scholar 

  15. Chiasson JL et al. Diabetologia. 2002;45(Suppl 2):A104

    Google Scholar 

  16. Marso SP, Daniels GH, Brown-Frandsen K et al (LEADER Steering Committee, LEADER Trial Investigators). Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Marso SP, Bain StC, Consoli A et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes: NEJM (online) September 16, 2016; doi: 10.1056/NEJMoa1607141

  18. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57

    Article  CAS  PubMed  Google Scholar 

  19. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28

    Article  CAS  PubMed  Google Scholar 

  20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71

    Article  CAS  PubMed  Google Scholar 

  21. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–89

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kardios am Wittenbergplatz, Ansbacher Straße 17–19, D-10787, Berlin, Deutschland

    Jürgen Scholze

Authors
  1. Jürgen Scholze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Scholze.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scholze, J. Kardiovaskuläre Sicherheit oraler Antidiabetika. MMW - Fortschritte der Medizin 159, 62–66 (2017). https://doi.org/10.1007/s15006-017-9162-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9162-z

Keywords

Search

Navigation